Am grateful to Katie Deighton of The Wall Street Journal for her interview about the challenges we faced commercialising a completely new & innovative period care product, and our pivot to the medical devices (drug delivery) space.

Understandably there hasn’t been anywhere near the press interest we had when things looked incredibly promising, to focus instead on the aftermath of what happens when a startup, despite all its herculean efforts, is forced to give up on its chosen path. So I welcomed this opportunity to share some of what had transpired, particularly the retail struggles we faced in a staid / taboo industry.

For now we’re firmly focused on the very exciting opportunity for our technology as a leak-free drug delivery platform with many applications – from ivf, miscarriage prevention and menopause, to bacterial vaginosis and beyond. There are so many relevant learnings from our past experiences and we look to the future with humility, gratefulness and excitement as our journey continues in the women’s health space.